Literature DB >> 14610096

Obesity, sleep apnea, and hypertension.

Robert Wolk1, Abu S M Shamsuzzaman, Virend K Somers.   

Abstract

Obesity has a high and rising prevalence and represents a major public health problem. Obstructive sleep apnea (OSA) is also common, affecting an estimated 15 million Americans, with a prevalence that is probably also rising as a consequence of increasing obesity. Epidemiologic data support a link between obesity and hypertension as well as between OSA and hypertension. For example, untreated OSA predisposes to an increased risk of new hypertension, and treatment of OSA lowers blood pressure, even during the daytime. Possible mechanisms whereby OSA may contribute to hypertension in obese individuals include sympathetic activation, hyperleptinemia, insulin resistance, elevated angiotensin II and aldosterone levels, oxidative and inflammatory stress, endothelial dysfunction, impaired baroreflex function, and perhaps by effects on renal function. The coexistence of OSA and obesity may have more widespread implications for cardiovascular control and dysfunction in obese individuals and may contribute to some of the clustering of abnormalities broadly defined as the metabolic syndrome. From the clinical and therapeutic perspectives, the presence of resistant hypertension and the absence of a nocturnal decrease in blood pressure in obese individuals should prompt the clinician to consider the diagnosis of OSA, especially if clinical symptoms suggestive of OSA (such as poor sleep quality, witnessed apnea, excessive daytime somnolence, and so forth) are also present.

Entities:  

Mesh:

Year:  2003        PMID: 14610096     DOI: 10.1161/01.HYP.0000101686.98973.A3

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  99 in total

Review 1.  Sleep and obesity: a focus on animal models.

Authors:  Vijayakumar Mavanji; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Neurosci Biobehav Rev       Date:  2012-01-16       Impact factor: 8.989

2.  Linda crane lecture 2008 "the challenge for the future: five steps to improve quality, incorporate prevention, maintain productivity, and have fun!".

Authors:  Hillegass Ellen
Journal:  Cardiopulm Phys Ther J       Date:  2008-06

3.  Factors associated with undiagnosed obstructive sleep apnoea in hypertensive primary care patients.

Authors:  Anders Broström; Ola Sunnergren; Kristofer Årestedt; Peter Johansson; Martin Ulander; Barbara Riegel; Eva Svanborg
Journal:  Scand J Prim Health Care       Date:  2012-06       Impact factor: 2.581

4.  A Systematic Review of Personality Disorders and Health Outcomes.

Authors:  Katherine L Dixon-Gordon; Diana J Whalen; Brianne K Layden; Alexander L Chapman
Journal:  Can Psychol       Date:  2015-10-15

5.  Population strategies to treat hypertension.

Authors:  Daniel T Lackland
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-08

Review 6.  Obstructive sleep apnea, hypertension, and wakefulness-promoting agents.

Authors:  Dan Carl; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

7.  Metabolic syndrome and sleep apnea.

Authors:  I Kostoglou-Athanassiou; P Athanassiou
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

Review 8.  Obstructive sleep apnea, hypertension and cardiovascular diseases.

Authors:  C Gonzaga; A Bertolami; M Bertolami; C Amodeo; D Calhoun
Journal:  J Hum Hypertens       Date:  2015-03-12       Impact factor: 3.012

9.  Knockdown of tyrosine hydroxylase in the nucleus of the solitary tract reduces elevated blood pressure during chronic intermittent hypoxia.

Authors:  Chandra Sekhar Bathina; Anuradha Rajulapati; Michelle Franzke; Kenta Yamamoto; J Thomas Cunningham; Steve Mifflin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-18       Impact factor: 3.619

Review 10.  Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment.

Authors:  Corey J Leinum; John M Dopp; Barbara J Morgan
Journal:  Nutr Clin Pract       Date:  2009-12       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.